Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Maxim Group Downgrades Pulse Biosciences to Hold

Maxim Group analyst Anthony Vendetti downgrades Pulse Biosciences (NASDAQ:PLSE) from Buy to Hold.

byBenzinga Newsdesk

September 21, 2022

1 minute read

Maxim Group analyst Anthony Vendetti downgrades Pulse Biosciences (NASDAQ:PLSE) from Buy to Hold.

Reata Pharmaceuticals Q2 EPS $(1.32) Beats $(2.08) Estimate, Sales $2.22M Beat $1.25M Estimate

By Benzinga Newsdesk

Today, 11:12 PM

Reata Pharmaceuticals (NASDAQ:RETA) reported quarterly losses of $(1.32) per share which beat the analyst consensus estimate of $(2.08) by 36.54 percent. This is a 7.32 percent decrease over losses of $(1.23) per share

RETA

Axcella Therapeutics Puts Development Of NASH Program Aside, Reduces Workforce By 85%

By Vandana Singh

Today, 11:12 PM

Axcella Health Inc (NASDAQ:AXLA) announced organizational and program updates, including a reprioritization of its programs for Long COVID Fatigue and…

AXLA

Telesat Canada Registers 5% Revenue Decline In Q3

By Anusuya Lahiri

Today, 11:12 PM

Telesat Canada reported a third-quarter FY21 revenue decline of 5% year-on-year to C$192.34 million. Telesat Canada’s principal shareholders…

LORL

Yahoo Exits China, Citing ‘Challenging Business And Legal Environment’

By Phil Hall

Today, 11:12 PM

Yahoo Inc. announced the withdrawal of its services from China, citing difficulties in maintaining operations within the nation’s restrictive technological environment.

APO

Maxim Group Downgrades Pulse Biosciences to Hold

Related Posts

Reata Pharmaceuticals Q2 EPS $(1.32) Beats $(2.08) Estimate, Sales $2.22M Beat $1.25M Estimate

Axcella Therapeutics Puts Development Of NASH Program Aside, Reduces Workforce By 85%

Telesat Canada Registers 5% Revenue Decline In Q3

Yahoo Exits China, Citing ‘Challenging Business And Legal Environment’